MedPath

Bilateral Versus Monolateral Repetitive Transcranial Stimulation in Depression

Phase 4
Completed
Conditions
Major Depression
Interventions
Device: repetitive transcranial stimulation (rTMS)
Device: unilateral stimulation
Registration Number
NCT00806143
Lead Sponsor
Institute of Neuroscience, Florence, Italy
Brief Summary

Repetitive transcranial magnetic stimulation (rTMS) has been recently FDA approved for the treatment of resistant depression. No accordance exists on which are the involved mechanisms of action and on which stimulation parameters, frequency and side are optimal.

Detailed Description

To compare these different procedures we study patients with unipolar recurrent resistant major depressive disorder in a double-blind, controlled trial randomized to either sequential bilaterally on the right and left dorsolateral prefrontal cortex (DLPFC) or monolaterally on the right DLPFC. Patients will be randomized to receive sequentially low-frequency rTMS at 1 Hz to the right DLPFC and high-frequency rTMS at 10 Hz rTMS to the left DLPFC, or to receive low-frequency rTMS at 1 Hz to the right DLPFC. Significant antidepressant effect as expressed by a reduction of Hamilton Depression Scale score will be recorded in both the groups of patients.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
16
Inclusion Criteria
  • Diagnostic and Statistical Manual-IV criteria for Depressive Major Episode Hamilton Rating Scale for Depression -28 (Ham-D)score ≥ 18
  • Failure to respond to a minimum of two courses of antidepressant medications for at least 6 weeks
Exclusion Criteria
  • Any comorbid axis I disorder (except simple and social phobia)
  • Any other significant medical, particularly neurologic, illnesses (seizures, head trauma and brain lesions)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1repetitive transcranial stimulation (rTMS)patients will undergo sequential bilateral rTMS treatment
2unilateral stimulationpatients will undergo unilateral low frequency right sided DLPFC rTMS
Primary Outcome Measures
NameTimeMethod
Hamilton Depression Scale (HAM-D)at baseline and 3rd week
Secondary Outcome Measures
NameTimeMethod
Clinical Global Impression Scale (CGI)baseline and 3rd week

Trial Locations

Locations (1)

Institute of Neuroscience

🇮🇹

Florence, Italy

© Copyright 2025. All Rights Reserved by MedPath